"Fatty Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Descriptor ID |
D005234
|
| MeSH Number(s) |
C06.552.241
|
| Concept/Terms |
Steatohepatitis- Steatohepatitis
- Steatohepatitides
- Steatosis of Liver
- Visceral Steatosis
- Steatoses, Visceral
- Steatosis, Visceral
- Visceral Steatoses
- Liver Steatosis
- Liver Steatoses
- Steatoses, Liver
- Steatosis, Liver
|
Below are MeSH descriptors whose meaning is more general than "Fatty Liver".
Below are MeSH descriptors whose meaning is more specific than "Fatty Liver".
This graph shows the total number of publications written about "Fatty Liver" by people in this website by year, and whether "Fatty Liver" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 2 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 5 | 0 | 5 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 5 | 8 |
| 2012 | 4 | 3 | 7 |
| 2013 | 3 | 2 | 5 |
| 2014 | 2 | 1 | 3 |
| 2015 | 3 | 2 | 5 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 4 | 2 | 6 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fatty Liver" by people in Profiles.
-
The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis. J Med Econ. 2024 Jan-Dec; 27(1):919-930.
-
Genetic Background Strongly Influences the Impact of Carrying the Thr92Ala-DIO2 Polymorphism in the Male Mouse. Endocrinology. 2024 May 27; 165(7).
-
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgrad Med. 2024 Apr; 136(3):229-245.
-
Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake - Authors' reply. Lancet Gastroenterol Hepatol. 2024 May; 9(5):409-410.
-
Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction. Nat Med. 2024 Apr; 30(4):933-936.
-
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024 Mar; 9(3):218-228.
-
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease. J Hepatol. 2024 Jul; 81(1):e20-e21.
-
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition'. Ann Hepatol. 2024 Jul-Aug; 29(4):101178.
-
Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart. Hepatology. 2024 06 01; 79(6):1252-1254.
-
Overexpression of HMGB1 in hepatocytes accelerates PTEN inactivation-induced liver cancer. Hepatol Commun. 2023 12 01; 7(12).